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Abstract
Purpose:  The  purpose  of  this  study  is  to  evaluate,  in  terms  of  number  of  examinations  and  how
effective  doses  are  distributed  by  location  and  chronology,  the  use  of  CT  and  nuclear  medicine
examinations  in  the  management  of  paediatric  oncology  patients.
Materials  and  methods:  This  was  a  retrospective  and  descriptive  study  that  included  57  children
(13  with  neonatal  neuroblastoma,  18  with  renal  tumours,  and  26  with  lymphoma)  over  a  5-
year  period,  with  the  length  of  monitoring  ranging  from  1  to  7  years.  All  CT  scans  and  nuclear
medicine  examinations  were  counted,  and  the  effective  doses  calculated.
Results: The  majority  of  the  examinations  were  performed  during  the  ﬁrst  year  of  management.
The  cumulative  effective  doses  ranged  from  7—152  mSv.  The  lymphoma  group  received  the
highest  doses,  but  fewer  than  10%  of  children  received  in  excess  of  100  mSv,  as  against  40%  in
the  North  American  study  published  by  Chawla  et  al.
Conclusion:  The  usage  of  irradiating  diagnostic  radiological  examinations  in  paediatric  oncology
produces  considerable  effective  doses,  which  must  lead  us  to  consider  evaluating  our  practices,
exploring  all  possible  ways  to  improve  protection  from  radiation,  especially  in  terms  of  justifying
investigations  and  using  alternatives.
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Over  the  course  of  more  than  two  decades,  we  have  seen
 continued  increase  in  the  number  of  imaging  examinations
erformed, especially  CT  scans.  In  parallel,  worries  over  the
isk of  the  carcinogenicity  of  ionising  radiation  continue  to
row, both  in  the  medical  and  scientiﬁc  world  and  for  the
eneral public,  which  has  led  the  authorities  to  legislate
n protection  from  radiation.  In  this  area,  the  paediatric
opulation has  been  subject  to  particularly  close  attention
ecause, due  to  their  cellular  sensitivity,  children  are  more
ulnerable to  ionising  radiation  and  the  suspected  long-term
ffects are  even  more  harmful  in  these  populations  with  a
onger life  expectancy.
Chronic  diseases  that  require  radiological  monitoring
ere the  ﬁrst  to  be  questioned  from  the  viewpoint  of  radia-
ion protection,  but  because  of  the  seriousness  of  paediatric
ncological disease,  it  has  never  been  the  focus  of  discus-
ions in  this  area.  Recently,  two  North  American  studies
ooked at  children  monitored  in  oncology  departments:  one
tudied all  imaging  modalities,  demonstrating  that  CT  and
uclear medicine  examinations  were  the  greatest  emitters
f ionising  radiation  in  diagnostic  imaging,  with  major  vari-
tions between  different  types  of  tumours;  in  this  study,
0% of  children  were  given  a  cumulative  effective  dose  of
00 mSv  and  22%  a  cumulative  dose  of  200  mSv  [1].  In  the
econd study,  which  took  in  positron  emission  tomography
ombined with  computed  tomography  (PET-CT),  27%  of  the
hildren were  given  a  cumulative  effective  dose  of  100  mSv
nd 10%,  200  mSv  [2].
In the  absence  of  a  similar  study  in  Europe,  we  looked
t the  practices  in  our  establishment  where  there  are  spe-
ialised paediatric  radiology  and  oncology  departments  that
se examination  protocols  and  monitoring  strategies  for
ncological disease  which  follow  the  French  and  European
ecommendations [3].
The  purpose  of  this  retrospective  and  descriptive  study
s to  evaluate  the  number  of  examinations  and  the  effective
oses delivered  to  these  children,  as  well  as  how  they  are
istributed around  the  body  and  chronologically  over  the
ourse of  management,  and  to  propose  possible  avenues  to
onsider for  changes  in  practices.
aterial and methods
tudy population
his  was  a  retrospective  study  into  57  children  who  were
onitored in  paediatric  oncology  at  Clocheville  Univer-
ity Hospital  in  Tours  and  had  been  diagnosed  with  cancer
etween 01/01/2005  and  31/12/2010.
Three  groups  of  disease  were  chosen:  neonatal  neu-
oblastomas, deﬁned  by  diagnosis  during  the  ﬁrst  year  of
ife, renal  tumours,  principally  nephroblastomas,  and  lym-
homas (both  Hodgkin  lymphoma  and  non-Hodgkin  B-cell
ymphoma).
nformation collectionor  each  patient,  demographic  and  clinical  data  were  gath-
red from  the  patients’  medical  records:  age,  sex,  type  of
ancer and  location,  treatment  (radiotherapy,  chemother-
py, surgery).
t
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Radiological  data  was  gathered  using  a  radiological  infor-
ation system  (Xplore® from  the  company  EDL)  and  PACS
Horizon Medical  Imaging TM from  the  company  McKesson).
or each  child,  all  computed  tomography  (CT)  and  nuclear
edicine (NM)  examinations  carried  out  starting  from  diag-
osis and  up  to  31/12/2011  (or  at  least  one  year  of
onitoring) were  brought  together,  and  the  time  to  the
xamination from  the  date  of  diagnosis  and  age  of  the  child
t the  time  of  the  examination  were  recorded.  The  number
f non-irradiating  examinations  (sonography,  MRI)  was  also
ounted in  order  to  assess  the  place  of  these  modalities  as
lternatives to  irradiating  investigations  in  our  practice.
CT  scans  were  carried  out  using  protocols  that  adjusted
he voltage  and  the  radiation  output  according  to  the  child’s
ody type  following  recommendations  from  the  Société
rancophone d’Imagerie  Pédiatrique  et  Prénatale  (French
ociety of  paediatric  and  prenatal  imaging)  and  the  paedi-
tric Niveaux  de  Référence  Diagnostiques  (NRD)  (diagnostic
eference levels)  [3].  The  data  collected  from  the  PACS
ystem (DICOM  data  and  images  from  the  examinations)
ere: anatomical  region  investigated,  number  of  times  each
egion was  investigated,  exposure  length,  volume  computed
omography dose  index  (CTDIvol),  and  the  Dose  Length  Prod-
ct (DLP).
When a  single  spiral  CT  of  the  chest,  abdomen  and  pelvis
as performed,  the  respective  DLP  for  each  anatomical
egion was  not  initially  available;  it  was  therefore  necessary
o determine,  by  consulting  the  images  from  each  exam-
nation, the  exposure  length  that  corresponded  to  each  of
hese anatomical  regions.  The  DLP  by  anatomical  region  was
btained by  multiplying  the  exposure  length  in  centimetres
y the  mean  CTDIvol  of  the  examination.
In  the  rare  cases  when  none  of  the  dosimetric  information
DLP, CTDIvol)  was  available  (fewer  than  5%  of  examina-
ions), the  doses  were  estimated  based  on  the  voltage  (kV)
nd radiation  output  (mAs)  as  these  parameters  are  always
vailable (DICOM  data  for  each  image).
The  data  gathered  for  the  nuclear  medicine  examina-
ions were:  type  of  radiopharmaceutical  injected  and  its
ctivity in  MBq  for  scintigraphy,  as  well  as  the  same  param-
ters as  for  CT  scans  if  the  examination  was  PET-CT  scan  or
 single-photon  emission  computed  tomography  combined
ith computed  tomography  (SPECT-CT).  The  activity  of  the
adiopharmaceutical injected  was  compliant  with  the  rec-
mmendations from  the  European  Association  of  Nuclear
edicine, and  depended  on  the  child’s  weight  [4—7].
stimation of the effective dose
he  cumulative  effective  doses  delivered  were  calculated
ased on  DLP  taking  two  different  multiplying  factors  into
ccount: ﬁrstly  a  coefﬁcient  for  conversion  of  tissue  sensi-
ivity based  on  the  Monte  Carlo  model  [8],  speciﬁc  to  the
natomical region  and  the  age  of  the  child,  and  secondly
 correction  coefﬁcient  that  took  into  account  the  diame-
er of  the  phantom  that  was  used  by  the  manufacturer  to
alibrate equipment  [9].In  nuclear  medicine,  the  effective  doses  from  the  injec-
ion of  radiopharmaceuticals  were  obtained  by  multiplying
he activity  injected  (in  MBq)  by  a  conversion  coefﬁcient
hat is  speciﬁc  to  the  radiopharmaceutical,  takes  the  age  of
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the  child  into  account,  and  is  validated  by  the  French  society
of nuclear  medicine  [10].
Estimation  of  effective  doses  in  PET-CT  and  SPECT-CT  was
in part  achieved  by  an  estimation  of  the  dose  generated  from
the injection  of  radiopharmaceuticals  (internal  source),  and
also the  dose  generated  by  CT  (external  source);  this  was
calculated in  the  same  way  as  for  CT  examinations.
Parameters assessed
We  analysed  the  characteristics  of  the  study  population
(age and  tumour  type).  For  each  child  in  each  group,  the
parameters assessed  were:  number  of  examinations,  num-
ber of  spiral  rotations  for  CT  explorations,  the  distribution  of
examinations over  time  and  by  anatomical  region,  the  effec-
tive doses,  and  a  comparison  between  the  use  of  irradiating
(CT and  NM)  and  non-irradiating  examinations  (sonography
and MRI).
In view  of  the  retrospective  and  descriptive  nature  of  this
study, the  only  statistical  data  used  were  the  calculations  of
means and  medians.
Results
Our  study  included  57  children,  26  girls  and  31  boys,  between
the ages  of  0  and  17  years,  with  a  mean  age  of  7  years  and  a
median age  of  6  years.  Thirteen  children  had  neuroblastoma,
18 had  a  renal  tumour,  and  26  had  lymphoma.
Four  children  were  deceased,  and  three  were  lost  to
follow-up, but  none  before  12  months  after  the  date  of
diagnosis. The  mean  length  of  monitoring  was  4  years,  all
groups combined,  with  a  minimum  of  1  year  and  maximum
follow-up of  7  years.
Counting incidences of imaging examinations
In  total,  421  examinations  were  carried  out,  of  which  325
were CT  scans  (70%)  and  96  were  nuclear  medicine  exami-
nations (51  PET-CT  scans,  4  SPECT-CT  scans,  or  on  average
0.9 PET-CT  scans  per  child),  and  the  distribution  of  these  by
disease is  shown  in  Table  1.  The  indications  for  the  exami-
nations were  studied,  and  in  98%  of  cases,  the  reason  was  to
assess the  tumour  itself,  while  in  2%  of  cases,  it  was  to  look
for complications.  Over  the  same  period,  the  children  in  the
study underwent  547  sonograms  and  52  MRI  scans  (Fig.  1).
A  mean  of  4.3  CT  scans  [1—13]  per  child  were  performed
in the  neuroblastoma  group,  4.2  [1—8]  in  the  renal  tumour
group, and  7.4  [1—13]  in  the  lymphoma  group.  The  mean
number of  spiral  acquisitions  per  examination  was  around
1, with  the  exception  of  the  renal  tumour  group  in  which  a
[
n
T
Table  1  Number  of  computed  tomography  and  nuclear  medic
Neuroblastomas
n  =  13
Number  of  CT  scans  56  
Number  of  PET  or  SPECT  scans  4  
Number  of  scintigrams  25  
Total  number  of  examinations  85  tions  in  pediatric  oncology  413
ean  of  1.75  spiral  acquisitions  were  carried  out  in  order  to
xplore the  abdomen  and  pelvis.
A  mean  of  1.9  [0—5]  scintigrams  per  child  were  per-
ormed in  the  neuroblastoma  group  (MIBG  I123  and  99Tc
one scintigraphy),  0.5  [0—2]  in  the  renal  tumour  group
99Tc bone  scintigraphy),  and  0.3  [0—1]  in  the  lymphoma
roup (99Tc  bone  scintigraphy).
For  PET  and  SPECT  combined  with  CT,  the  mean  number
f examinations  carried  out  per  child  was  0.3  [0—1]  in  the
euroblastoma group  (MIBG  I123  SPECT-CT),  and  1.9  [0—5]
n the  lymphoma  group  (18-FDG  PET-CT),  while  the  renal
umour group  did  not  undergo  any  of  these  examinations.
With  regard  to  the  chronology  of  these  examinations:
ith all  tumours  combined,  70%  of  CT  scans  and  85%  of
uclear medicine  examinations  were  performed  during  the
rst year  after  diagnosis.
In the  solid  tumour  groups,  there  was  no  CT  or  NM  explo-
ation beyond  38  months;  for  the  lymphoma  group,  6%  of
xaminations (13  CT  scans  and  3  PET  scans)  were  carried
ut after  the  40th  month  of  follow-up.
valuation of effective doses
ll  modalities  considered  together,  the  total  effective  doses
elivered for  each  patient  are  summarised  in  Fig.  2.  For
olid tumours,  except  for  one  case  of  neuroblastoma  with
ultiple metastases,  the  total  doses  delivered  per  patient
ere always  below  50  mSv;  by  contrast,  a  third  of  lymphoma
atients received  in  excess  of  this  value  (Fig.  3).
With  a mean  cumulative  effective  dose  per  child  of
3 mSv  in  the  neuroblastoma  group,  25  mSv  in  the  renal
umour group,  and  45.5  mSv  in  the  lymphoma  group,  CT
ccounts for  73%  of  the  total  diagnostic  dose  in  our  study
75%, 95%  and  67%  of  the  total  dose  for  each  group  respec-
ively).
The distribution  of  effective  doses  from  CT  (excluding
ET-CT) by  anatomical  region  explored  is  summarised  in
able 2  and  Fig.  4:  Table  2  shows  the  mean  effective  dose
or a  CT  scan  (excluding  PET-CT)  by  anatomical  region,  while
ig. 4  shows  the  mean  cumulative  effective  doses  per  child
nd by  anatomical  region.
The  part  of  the  effective  dose  accounted  for  by  the
njection of  radiopharmaceuticals  was  24%,  5%  and  17%
or neuroblastomas,  renal  tumours,  and  lymphomas  respec-
ively, with  a mean  cumulative  effective  dose  per  child
n each  group  of  7.3  [0—19]  mSv,  1.3  [0—6]  mSv,  and  10.9
0—34] mSv  respectively.
The mean  effective  doses  generated  by  the  CT  compo-
ent of  PET  and  SPECT-CT  are  brought  together  in  Table  3.
hey account  for  1%,  0  and  16%  of  the  total  dose  for
ine  examinations  in  the  study.
Renal tumours
n =  18
Lymphomas
n  =  26
Total
76  193  325
0  51  55
9  7  41
85  251  421
414  C.  Vallin  et  al.
Figure 1. Comparison of the different imaging modalities (CT scan, nuclear medicine, sonography, MRI): mean number of examinations
performed in each group.
Figure 2. Distribution of total cumulative effective doses (CT scan and nuclear medicine) in each tumour group.
Table  2 Mean  effective  dose  per  CT  scan  (excluding  PET-CT)  in  each  tumour  group  in  mSv.
Head  Neck  Chest  Abdomen-pelvis
Neuroblastomas  (n  =  13)  4.1  1.0  2.6  3.8
Renal  tumours  (n  =  18)  4.1  0.6  1.9  5.1
Lymphomas  (n  =  26)  3.2  1.1  2.6  4.7
The  use  of  computed  tomography  and  nuclear  medicine  examinations  in  pediatric  oncology  415
Figure 3. Distribution by percentage of children and by values of cumulative effective doses reached in each tumour group (CT scan and
nuclear medicine examinations).
Figure 4. Distribution of mean cumulative effective doses per child, by anatomical region and tumour group, as generated by CT.
Table  3  Mean  effective  doses  per  examination  for  the  CT  component  of  PET-CT  expressed  in  mSv.
Head  Neck  Chest  Abdomen-pelvis
Neuroblastomas  (n  =  13)  0  0 1.1  1.3
Renal  tumours  (n  =  18)  0  0 0  0
Lymphomas  (n  =  26)  0.1  0.7  1.7  3.5
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euroblastomas,  renal  tumours,  and  lymphomas  respec-
ively.  In  the  speciﬁc  case  of  lymphoma,  33%  of  the  effective
ose was  generated  by  nuclear  medicine,  2%  of  which  by
9Tc bone  scintigraphy  and  31%  by  18-FDG  PET-CT  (53%  of
his dose  was  generated  by  the  CT  component  of  PET-CT
nd 47%  by  the  18-FDG  injection),  with  a  mean  effective
ose per  PET-CT  scan  and  per  child  estimated  at  9.9  mSv.
iscussion
rotection  from  radiation  is  today  the  focus  for  concerns  in
aediatric imaging,  with  particularly  close  attention  being
aid to  performing  and  optimising  use  of  CT.  In  view  of
he seriousness  of  the  diseases  and  the  need  for  long-term
atient follow-up,  paediatric  oncology,  along  with  trauma-
ology, is  one  of  the  heaviest  users  of  computed  tomography
n paediatric  radiology.  There  has  been  practically  no  assess-
ent of  the  need  to  use  CT  in  this  ﬁeld,  in  contrast  to  in
on-malignant disease  [11—16].  This  relative  lack  of  inter-
st is  probably  due  to  the  fact  that  with  tumours,  the
isks of  diagnostic  radiation  remains  signiﬁcantly  below  the
xpected diagnostic  beneﬁts,  and  that  imaging  has  been
onsidered to  be  a  negligible  source  of  ionising  radiation
ompared to  radiotherapy.
However,  it  must  be  acknowledged  that  there  is  mini-
al recourse  to  radiotherapy  in  paediatric  practice  (21%  of
he children  in  our  study,  mainly  for  lymphomas)  and  that
he doses  delivered  during  diagnostic  imaging  are  sometimes
igniﬁcant (over  100  mSv).  Two  studies  assessed  the  number
f examinations  and  the  effective  dose  delivered  in  pae-
iatric oncology:  Ahmed’s  Canadian  team,  which  looked  at
50 children  and  evaluated  CT  and  nuclear  medicine,  and
he American  team  of  Chawla  et  al.,  which  assessed  the  use
f  PET-CT  in  78  children  [1,2].
ethodological analysis
e  chose  to  study  these  three  diseases  because  of  the
ellular radiosensitivity  of  young  (renal  tumours)  and  very
oung (neuroblastomas)  children,  and  the  signiﬁcant  num-
er of  irradiating  examinations  carried  out  in  older  children
lymphoma). Other  types  of  tumours  were  excluded  either
ecause they  are  much  less  common,  or  because  monitoring
pproaches less  often  require  CT  or  nuclear  medicine:  this
as the  case  for  leukaemia,  but  above  all  for  brain  tumours,
hich are  almost  always  monitored  by  MRI  (except  for  acute
omplications).
Plain ﬁlm  radiography  was  not  included  because  this
odality has  been  demonstrated  to  generate  only  a  minor
art of  the  total  dose  (44%  of  the  total  number  of  examina-
ions but  only  1%  of  the  cumulative  effective  dose  according
o Ahmed  et  al.  [1]).
imitations of the study
o  simplify  the  collection  of  dosimetric  information,  we
ould have  simply  based  our  ﬁndings  on  the  department
rotocols and  used  mean  values  per  examination,  as  some
uthors have  done,  but  we  chose  to  reﬂect  the  reality  of
ur practices  as  closely  as  possible  by  considering  the  actual
ata from  each  examination.
c
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Our  study,  like  those  in  the  literature,  contains  some
lements of  bias:  not  so  much  in  terms  of  counting  the  num-
er of  procedures  (the  children  who  were  lost  to  follow-up
r deceased  were  in  fact  the  ones  who  were  most  often
onitored beyond  the  ﬁrst  year  of  management)  but  in  the
ifﬁculties encountered  in  evaluating  the  dose.
As  discussed  above,  the  ﬁrst  difﬁculty  concerned  assess-
ng the  distribution  of  the  dose  delivered  by  anatomical
egion after  the  fact.
The second  problem  was  related  to  our  determination  to
scertain the  effective  dose  accounted  for  by  each  of  the
ifferent types  of  examination.  Of  course,  we  could  have
estricted the  study  to  look  as  only  the  doses  delivered,  using
he  most  objective  data,  which  is  that  collected  at  the  time
f the  examination  (mainly  DPL),  but  converting  this  into
ffective doses,  in  spite  of  the  imperfections  of  this  pro-
ess, did  seem  to  us  to  be  necessary  in  order  to  be  able
o assess  several  types  of  imaging  and  to  compare  our  data
o those  in  the  literature  and  to  background  radiation.  The
ffective dose,  which  is  not  a  directly  measurable  physical
uantity, can  only  be  estimated  by  using  mathematical  cal-
ulations that  take  into  account  the  tissue  radiosensitivity
f the  various  anatomical  regions  exposed.  The  problem  is
till more  complex  in  children  due  to  growth,  meaning  that
onversion coefﬁcients  are  needed  for  different  anatomical
egions and  for  age  range.  These  imperfections  are  not  spe-
iﬁc to  our  study;  rather  they  are  common  to  all  the  studies
n the  literature.
In nuclear  medicine,  the  effective  dose  is  even  more
hallenging to  estimate,  because  the  radiopharmaceutical
racers injected  distribute  through  the  body  very  unevenly;
his means  that  the  coefﬁcients  used  to  estimate  the  dose
o the  organs  and  the  total  effective  dose  are  both  approx-
mate.
nalysis of the results
ith  regard  to  the  chronology  of  examinations,  irrespective
f tumour  group,  we  noticed  that  explorations  peaked  during
he ﬁrst  year  after  diagnosis,  which  is  accounted  for  by  the
nitial investigations  and  the  early  assessment  of  treatment
fﬁcacy. After  full  remission  is  achieved,  radiological  follow-
p is  initiated,  but  this  process  is  less  standardised:  for  solid
umours, CT  and  NM  are  not  necessarily  called  for,  while
n the  lymphoma  group,  one  in  every  two  children  was  still
aving a  CT  scan  or  PET-CT  after  the  third  year  of  follow-up.
In  terms  of  the  number  of  CT  scans  (excluding  PET-CT),
e noticed  a  large  disparity  between  solid  tumours  and
ymphomas, although  the  mean  length  of  monitoring  was
quivalent. In  the  case  of  solid  tumours,  the  mean  number
f CT  scans  per  child  was  almost  identical  for  neuroblas-
omas and  solid  tumours,  but  a  closer  analysis  revealed  that
here was  greater  variation  within  the  neuroblastoma  group
between 1  and  13  CT  scans  were  carried  out  per  patient),
ue to  the  signiﬁcant  differences  in  these  tumours  depend-
ng on  prognostic  markers  (location,  extension,  spread,
umour markers).  The  mean  number  of  examinations  per
hild counted  by  Ahmed  et  al.  for  solid  tumours  was  notice-
bly higher  than  in  our  study  (12  as  against  3),  which  is
robably due  to  the  more  frequent  usage  of  sonography  in
ur practice  than  in  North  America.
mina
d
t
a
t
C
o
(
h
r
c
w
2
o
i
d
o
b
1
r
s
f
5
l
t
t
i
p
i
w
r
o
e
b
t
r
c
d
s
n
e
a
w
r
n
p
e
b
t
p
n
c
pThe  use  of  computed  tomography  and  nuclear  medicine  exa
The  lymphoma  group  was  the  one  that  accumulated  the
largest number  of  examinations  (a  mean  of  7.4  examinations
per child),  due  to  closer  and  more  prolonged  monitoring,  but
also  because  of  the  spread  of  the  disease,  especially  in  view
of possible  involvement  above  the  diaphragm,  an  area  that
is inaccessible  to  ultrasound  exploration.  Our  ﬁgures  for  this
disease are  very  similar  to  those  of  Ahmed  et  al.
The  effective  dose  values  were  determined  by  the
anatomical distribution  of  the  number  of  examinations  and
the number  of  spiral  acquisitions  (for  which  the  variations
observed were  due  to  the  different  diseases  and  their  usual
sites). The  mean  dose  per  examination  for  each  anatomi-
cal region  was  overall  equivalent  across  the  three  groups
because the  higher  DPLs  in  the  lymphoma  group  (due  to  the
age and  body  shape  of  the  children)  were  counterbalanced
by more  reliable  conversion  coefﬁcients.
In  terms  of  effective  dose  per  spiral  acquisition,  our  data
are similar  to  those  in  the  literature  for  the  skull  and  brain
region and  the  chest  because  our  protocols  are  compliant
with NRD  guidelines,  but  they  are  lower  for  exploration  of
the abdomen  and  pelvis;  this  is  probably  because  the  proto-
cols included  for  this  anatomical  region  are  more  variable,
and in  our  institution,  we  have  had  an  optimisation  policy  in
place for  a  number  of  years,  even  before  the  NRD  guidelines
were established.
The role  of  nuclear  medicine  varied  depending  on  tumour
group: it  was  widely  used  in  the  lymphoma  and  neurob-
lastoma group,  but  it  accounted  for  only  a  small  part  of
the effective  dose  in  the  renal  tumour  group,  as  expected,
because of  the  recommendations  of  European  protocols
for the  management  of  these  types  of  tumours  [17].
Compared to  data  from  the  literature,  with  all  nuclear
medicine explorations  considered  together,  we  performed
fewer explorations  per  child,  and  this  gap  was  more  marked
in the  neuroblastoma  group,  with  a  mean  of  15  nuclear
medicine examinations  being  carried  out  in  the  Ahmed  et  al.
study, with  ﬁgures  peaking  at  46  examinations;  however,
these differences  may  simply  be  due  to  the  fact  that  we
focused only  on  the  neonatal  form  of  this  disease.
A  comparison  of  our  data  for  PET-CT  with  those  from  the
recent American  study  by  Chawla  et  al.  showed  that  we
carried out  on  average  fewer  PET-CT  scans  per  child  (0.9
as against  3.2),  and  with  much  lower  mean  effective  doses
per examination  (9.9  mSv  as  against  24.8  mSv)  [2].  In  our
study, just  over  half  of  the  effective  dose  of  PET-CT  was
accounted for  by  the  CT  component  (53%),  with  the  other
half accounted  for  by  the  18-FDG  injection,  in  contrast  to
the Chawla  et  al.  study,  in  which  81%  of  the  dose  was  gener-
ated by  the  CT  scan.  This  is  probably  due  to  the  acquisition
parameters used  for  the  CT  scans.
Taking  all  radiopharmaceutical  tracers  into  account
(scintigraphy and  PET  or  SPECT),  we  noted  that  this  source
of radiation  dose  was  not  negligible,  since  it  was  responsible
for one  sixth  of  the  total  effective  dose  in  the  neuroblastoma
and lymphoma  groups,  while  still  remaining  compliant  with
the recommendations  on  injected  activity  from  the  French
society of  nuclear  medicine  [5].
Considering  all  imaging  modalities  together,  the  total
cumulative effective  doses  ranged  from  7  to  152  mSv,  with
the majority  of  children  (73%)  receiving  doses  in  excess  of
20 mSv  (this  equates  to  ten  years  exposure  to  background
radiation or  several  hundred  chest  radiographs).
ﬁ
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The lymphoma  group  accumulated  the  highest  effective
oses, with  ﬁve  children  receiving  over  100  mSv  (equivalent
o 40  years  of  exposure  to  background  radiation).  The  rel-
tive overexposure  of  this  group  may  be  related  in  part  to
he frequent  use  (11  on  average  for  these  ﬁve  children)  of
T studies  of  multiple  regions  (chest-abdomen-pelvis,  and
ften neck  too),  as  well  as  the  signiﬁcant  recourse  to  PET-CT
three on  average  for  these  ﬁve  children).
The  Ahmed  et  al.  study  published  ﬁgures  noticeably
igher than  ours:  indeed,  fewer  than  10%  of  our  children
eceived a  dose  in  excess  of  100  mSv  while  40%  of  the
hildren in  the  Ahmed  et  al.  study  passed  this  threshold,
ith a considerable  number  (22%)  receiving  in  excess  of
00 mSv,  the  maximum  exposure  being  642  mSv  (152  mSv  in
ur study).
The risk  of  the  low  doses  of  radiation  from  diagnostic
maging causing  cancer  has  been  the  topic  of  numerous
ebates within  the  French  Academy  of  Science  [18].  In  spite
f the  strongly  held  belief  that  there  is  a  linear  relationship
etween dose  and  risk  of  carcinogenicity,  the  threshold  of
00 mSv  is  often  cited  in  the  literature  [19—21].  The  most
ecent of  these  studies,  from  Pearce  et  al.,  appears  to  even
how an  increase  in  the  risk  of  brain  tumours  and  leukaemia
or lower  doses:  a  cumulative  dose  in  childhood  in  excess  of
0 mSv  to  the  bone  marrow  is  suggested  to  triple  the  risk  of
eukaemia while  a  dose  over  60  mSv  to  the  brain  is  suggested
o triple  the  risk  of  a  brain  tumour  [22].
All  of  these  points  are  at  the  centre  of  our  considera-
ion of  the  evaluation  of  our  practice.  While  it  is  clear  that
n terms  of  number  of  examinations  and  dose  our  study
roduced ﬁgures  below  those  found  in  the  literature,  it
s no  less  essential  for  us  to  explore  all  possible  ways  in
hich we  can  improve  radiation  protection.  Children  always
eceive particularly  close  attention  in  this  area  because
f the  radiosensitivity  of  their  cells  and  their  longer  life
xpectancy; this  is  still  applicable  in  paediatric  oncology
ecause, when  all  histological  tumour  types  are  considered
ogether, a  complete  cure  is  achieved  in  75%  of  cases  [23].
The  European  Council  directive  97/43/Euratom  and  more
ecently the  French  decree  of  24th  October  2011  con-
erning diagnostic  reference  levels  (niveaux  de  reference
iagnostiques [NRD])  in  radiology  and  nuclear  medicine
trengthened our  control  of  radiation  produced  by  CT  scan-
ing in  paediatrics  and  demanded  better  justiﬁcation  for
xaminations, optimisation  of  the  acquisition  parameters,
nd use  of  diagnostic  reference  levels  [24—26].
When  it  comes  to  justifying  investigations,  a  process
hich is  founded  on  a  case  by  case  approach  and  a
isk-beneﬁt balance,  there  are  already  national  and  inter-
ational protocols  that  govern  the  overall  management  of
atients in  the  ﬁeld  of  oncology  [27].  It  must  be  acknowl-
dged that  the  radiation  risk  from  diagnostic  imaging  has  not
efore  today  been  seriously  taken  into  account  in  drawing  up
hese protocols.  Our  study  brings  up  a  number  of  objective
oints that  will  feed  into  future  discussions.  For  example,  for
ephroblastomas, we  note  that  the  cumulative  dose  to  the
hest is  far  from  negligible  while  according  to  the  European
rotocols, metastasis  is  still  in  theory  diagnosed  by  plain
lm chest  radiography;  the  vagueness  that  persists  concern-
ng the  prognostic  and  therapeutic  value  of  routine  CT  to
ook for  (and  then  monitor)  micronodules  is  undoubtedly  at
he root  of  the  overexposure  to  radiation  in  this  population.
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In  terms  of  alternative  examinations,  paediatric  radiol-
gy is  distinct  from  practices  in  adults,  and  those  in  North
merica, in  its  greater  use  of  sonography,  which  is  acknowl-
dged to  perform  well  in  paediatrics:  thus,  in  our  solid
umour population,  the  number  of  sonograms  carried  out
as 2—3  times  greater  than  the  number  of  CT  scans.  Further
rogress is  still  possible,  especially  in  lymphoma,  in  which
nlarged cervical  lymph  nodes  are  still  often  investigated  by
T.
Greater use  of  MRI  must  be  considered  as  an  alterna-
ive to  CT  in  exploration  of  the  abdomen  and  pelvis,  but
lso in  nuclear  medicine  when  looking  for  bone  involvement
28,29]. If  use  of  MRI  could  be  extended  to  the  chest,  were
his to  become  technically  possible  and  medically  validated,
his would  mark  a  true  advance  into  the  future,  especially
n the  management  of  lymphoma.
Paediatric  protocols  for  optimisation  are  widely  avail-
ble, and  their  use  is  essential  [30—34].  Adjusting  the
arameters of  the  examination  to  the  patient’s  body  shape
nd comparison  with  the  NRD  serves  as  a  benchmark  of  good
ractice. Recent  technological  advances  in  both  detectors
nd iterative  reconstruction  systems  mean  that  we  may  hope
or  a  real  reduction  in  doses  delivered.
Optimisation  also  includes  restricting  the  number  of  spi-
al acquisitions  carried  out:  as  our  study  shows,  obtaining
wo acquisitions  of  the  abdomen  may  sometimes  be  nec-
ssary at  the  diagnostic  stage  or  preoperatively  for  solid
umours (vascular  mapping,  looking  for  venous  thrombosis),
ut a  single  spiral  acquisition  must  remain  the  rule,  espe-
ially during  follow-up  [35].
These  practices  for  optimising  computed  tomography  are
lso applicable  to  the  CT  component  of  PET-CT  and  SPECT-
T, but  the  main  question  in  this  area  remains  whether  it  will
ecome possible  to  perform  a  single  CT  scan  that  can  play
 dual  role,  both  in  morphological  radiology  and  functional
maging.
onclusion
his  study  enriches  the  current  literature  through  the  con-
ideration of  practice  in  Europe  in  terms  of  the  use  of  the
iagnostic radiological  examinations  emitting  the  greatest
adiation in  the  management  of  children  in  paediatric  oncol-
gy.
It shows  that  the  majority  of  examinations  are  car-
ied out  during  the  ﬁrst  year  of  management.  CT  scans
nd nuclear  medicine  examinations  produced  considerable
ffective doses,  ranging  from  7  to  152  mSv,  with  signiﬁcant
ariation by  disease;  two  groups  of  tumours  were  identiﬁed:
n the  one  hand,  solid  tumours  received  individual  cumu-
ative effective  doses  below  50  mSv,  while  the  lymphoma
roup, in  which  CT  of  the  neck,  chest,  abdomen  and  pelvis
nd PET-CT  were  more  frequently  used,  were  exposed  to
he highest  cumulative  effective  doses,  sometimes  exceed-
ng 100  mSv.  Although  fewer  than  10%  of  patients  were  given
hese kinds  of  doses,  and  these  cumulative  effective  doses
ere overall  below  those  found  in  the  literature,  this  does
ot, in  view  of  the  suspected  long-term  effects,  release
s from  the  obligation  to  make  every  attempt  to  minimise
rradiating examinations  as  far  as  possible,  by  applying  the
rinciples of  justifying  investigations,  optimising  protocols,
[C.  Vallin  et  al.
nd  suggesting  alternatives  such  as  sonography  and  MRI
henever possible.
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